{
    "clinical_study": {
        "@rank": "85830", 
        "acronym": "RESOunD", 
        "arm_group": {
            "arm_group_label": "Rebif\u00ae via Rebidose\u00ae auto-injector", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment\n      satisfaction in patients with relapsing forms of Multiple Sclerosis (MS)  who are currently\n      being treated with, but are considering discontinuing treatment with Tecfidera\u2122."
        }, 
        "brief_title": "RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key inclusion Criteria:\n\n          -  Diagnosis of relapsing form of MS\n\n          -  Have declared a desire/plan to discontinue treatment with Tecfidera due to\n             tolerability issues and/or lack of efficacy\n\n          -  Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Key exclusion Criteria:\n\n          -  Pregnant or lactating\n\n          -  Significant renal or hepatic impairment or other significant disease  that would\n             compromise adherence and completion of the trial\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117050", 
            "org_study_id": "EMR200136-586"
        }, 
        "intervention": {
            "arm_group_label": "Rebif\u00ae via Rebidose\u00ae auto-injector", 
            "description": "Rebif\u00ae will be administered subcutaneously  three times a week at a dose of 8.8 to 44 mcg in initial titration schedule (5 weeks), followed by Rebif\u00ae 44 mcg subcutaneously three times a week by using Rebif\u00ae Rebidose\u00ae auto-injector device till Week 24.", 
            "intervention_name": "Rebif\u00ae", 
            "intervention_type": "Drug", 
            "other_name": [
                "Rebif\u00ae", 
                "interferon-beta-1a"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Dimethyl fumarate", 
                "Interferon beta 1a"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Multiple Sclerosis", 
            "Rebif \u00ae", 
            "Tecfidera \u2122", 
            "treatment change"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "The North American Research Committee on Multiple Sclerosis - Information about the PDDS Questionaire", 
            "url": "http://www.narcoms.org/pdds"
        }, 
        "location": {
            "contact": {
                "last_name": "EMD Serono Medical Information", 
                "phone": "888-275-7376"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Call EMD Serono Medical Information for information on recruiting sites"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera\u2122 to Rebif\u00ae 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)", 
        "overall_contact": {
            "last_name": "EMD Serono Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Treatment satisfaction score determined by the global satisfaction sub-scale of the Treatment Satisfaction Questionnaire for Medication (TSQM [Version II]) at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117050"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Patient-Determined Disease Steps Questionnaire (PDDS) score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change from baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change from baseline in TSQM (Version II) - Total score at Week 12 and Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, and Week 24"
            }, 
            {
                "measure": "Change from baseline in  TSQM (Version II) - Medication effectiveness, side effects, and convenience subscale scores at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change from baseline in TSQM (Version II) - Global satisfaction, medication effectiveness, side effects, and convenience subscale scores at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from baseline in Work Productivity and Activity Impairment- General Health (WPAI-GH) questionnaire score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change From Baseline in number of Combined Unique Active (CUA) Lesions, New Time or Enlarging Constant 2 (T2) Lesions, and New Gadolinium Enhanced (Gd+) Time Constant 1 (T1) Lesions at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Annualized Relapse Rate (ARR)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}